KR20240155278A - 화농성 한선염의 치료에서 사용하기 위한 레미브루티닙 - Google Patents

화농성 한선염의 치료에서 사용하기 위한 레미브루티닙 Download PDF

Info

Publication number
KR20240155278A
KR20240155278A KR1020247031567A KR20247031567A KR20240155278A KR 20240155278 A KR20240155278 A KR 20240155278A KR 1020247031567 A KR1020247031567 A KR 1020247031567A KR 20247031567 A KR20247031567 A KR 20247031567A KR 20240155278 A KR20240155278 A KR 20240155278A
Authority
KR
South Korea
Prior art keywords
lou064
treatment
patient
administered
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247031567A
Other languages
English (en)
Korean (ko)
Inventor
소우비크 브하타차르야
브루노 비트
브루노 체니
고든 그라함
미하엘 융케
크리스티안 뢰셰
카린 라프
킴-힌 진
조나스 벤자민 치러
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20240155278A publication Critical patent/KR20240155278A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247031567A 2022-02-28 2023-02-27 화농성 한선염의 치료에서 사용하기 위한 레미브루티닙 Pending KR20240155278A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US63/314,572 2022-02-28
US202263369016P 2022-07-21 2022-07-21
US63/369,016 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
KR20240155278A true KR20240155278A (ko) 2024-10-28

Family

ID=85570288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031567A Pending KR20240155278A (ko) 2022-02-28 2023-02-27 화농성 한선염의 치료에서 사용하기 위한 레미브루티닙

Country Status (11)

Country Link
US (1) US20250099465A1 (https=)
EP (1) EP4486346A1 (https=)
JP (2) JP7696006B2 (https=)
KR (1) KR20240155278A (https=)
CN (1) CN120617264A (https=)
AU (1) AU2023225222A1 (https=)
CA (1) CA3251002A1 (https=)
IL (1) IL314205A (https=)
MX (1) MX2024010392A (https=)
TW (1) TW202342048A (https=)
WO (1) WO2023161887A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
LT3380465T (lt) 2015-11-26 2020-11-10 Novartis Ag Diamino piridino dariniai
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP7007374B2 (ja) 2016-09-23 2022-01-24 ノバルティス アーゲー 腱及び／又は靭帯損傷に使用するためのインダゾール化合物
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
MX2021014161A (es) 2019-05-23 2022-01-04 Novartis Ag Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
HRP20251001T1 (hr) 2019-05-23 2025-10-24 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije
BR112021023054A2 (pt) * 2019-05-23 2022-03-29 Novartis Ag Formas cristalinas de um inibidor de btk
TW202142237A (zh) * 2020-01-08 2021-11-16 美商普林斯匹亞生物製藥公司 包含2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈之局部醫藥組成物
TWI905371B (zh) 2021-01-26 2025-11-21 瑞士商諾華公司 藥物組成物

Also Published As

Publication number Publication date
EP4486346A1 (en) 2025-01-08
JP2024511938A (ja) 2024-03-18
JP7696006B2 (ja) 2025-06-19
WO2023161887A1 (en) 2023-08-31
IL314205A (en) 2024-09-01
TW202342048A (zh) 2023-11-01
CA3251002A1 (en) 2023-08-31
MX2024010392A (es) 2024-09-06
US20250099465A1 (en) 2025-03-27
AU2023225222A1 (en) 2024-07-25
JP2025134747A (ja) 2025-09-17
CN120617264A (zh) 2025-09-12

Similar Documents

Publication Publication Date Title
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
Toldo et al. Interleukin‐1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse
Sá et al. Inflammasomes and dermatology
KR102258698B1 (ko) B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
JP2024511141A (ja) オリスミラストによる化膿性汗腺炎の治療
EP3972604A1 (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
JP2010508277A (ja) 癌を検出および抑制するための方法
JP2025134747A (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
AU2017227515B2 (en) Imatinib for use in the treatment of stroke
Xiang et al. Tiamulin inhibits TNF-α and alleviates psoriasis-like dermatitis
AU2019210999B2 (en) Use of minaprine to reduce tumor growth
JP7594124B2 (ja) Ｌｏｕ０６４を使用した治療の方法
EA051701B1 (ru) Ремибрутиниб для применения в лечении гнойного гидраденита
CN118742308A (zh) 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼
CN117479936A (zh) 用奥瑞司特治疗化脓性汗腺炎
TW202539668A (zh) 使用索樂匹尼布處置免疫性血小板減少症的方法
EA052375B1 (ru) Варианты комбинированного лечения меланомы
El Rakaawi et al. THU0397 Efficacy of pamidronate in children with osteogenesis imperfecta: An open prospective study

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302